Using data from the peer-reviewed literature, government disease-surveillance programs, and the US Census, authors developed a customizable model to estimate human and economic burden caused by four major adult vaccine-preventable diseases in 2013 in
the United States.
An evaluation of cost-effectiveness to support the vaccination of
immunocompetent Americans aged ≥60 years was performed. The study showed that the herpes zoster vaccine could eliminate thousands of cases of herpes zoster, hospitalizations, and prescriptions in vaccinated adults.
A savings of $82 million to $103
million in healthcare costs associated with the diagnosis and treatment of herpes zoster, postherpetic neuralgia, and other complications associated
with herpes zoster
Cost per QALY gained (payer perspective): $18,439 (cost savings of $50,232)